Literature DB >> 28327356

Type 2 inositol trisphosphate receptor gene expression in hepatocytes is regulated by cyclic AMP.

Emma Kruglov1, Meenakshisundaram Ananthanarayanan1, Pedro Sousa1, Jittima Weerachayaphorn1, Mateus T Guerra1, Michael H Nathanson2.   

Abstract

The type 2 inositol 1,4,5-trisphosphate receptor (IP3R2) is the principal intracellular Ca2+ release channel in hepatocytes, and so is important for bile secretion and other functions. IP3R2 activity is regulated in part by post-translational modifications but little is known about transcriptional regulation of its expression. We found that both IP3R2 mRNA and protein levels in liver were increased during fasting. Treatment of hepatocytes with forskolin or 8-CPT-cAMP also increased IP3R2, and this was reduced by actinomycin D. Analysis of the IP3R2 promoter revealed five CREs, and CREB potently increased promoter activity. Mutation of CRE4 or CRE5 decreased induction by CREB, and ChIP assay showed recruitment of CREB to these sites. Adenylyl cyclase (AC) 6 and 9 were the principal AC isoforms detected in rat hepatocytes, and silencing either one decreased organic anion secretion, which depends on IP3R2. Secretion furthermore was increased by overnight but not acute treatment with forskolin or 8-CPT-cAMP. These findings provide evidence that IP3R2 expression is transcriptionally regulated by cAMP via CREB binding to CRE elements in its promoter. The findings furthermore suggest that this mechanism is relevant for hormonal regulation of bile secretion.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bile secretion; Calcium signaling; Cyclic AMP; Hepatocytes; Type 2 inositol 1,4,5-trisphosphate receptor

Mesh:

Substances:

Year:  2017        PMID: 28327356      PMCID: PMC5421629          DOI: 10.1016/j.bbrc.2017.03.086

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

1.  Mammalian target of rapamycin (mTOR) phosphorylates inositol 1,4,5-trisphosphate receptor type 2 and increases its Ca(2+) release activity.

Authors:  Yannik Régimbald-Dumas; Marc-Olivier Frégeau; Gaétan Guillemette
Journal:  Cell Signal       Date:  2010-08-18       Impact factor: 4.315

2.  The type II inositol 1,4,5-trisphosphate receptor can trigger Ca2+ waves in rat hepatocytes.

Authors:  Keiji Hirata; Thomas Pusl; Allison F O'Neill; Jonathan A Dranoff; Michael H Nathanson
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

3.  Cytosolic calcium regulates liver regeneration in the rat.

Authors:  Laura Lagoudakis; Isabelle Garcin; Boris Julien; Kis Nahum; Dawidson A Gomes; Laurent Combettes; Michael H Nathanson; Thierry Tordjmann
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

4.  Regulation of multidrug resistance-associated protein 2 by calcium signaling in mouse liver.

Authors:  Laura N Cruz; Mateus T Guerra; Emma Kruglov; Albert Mennone; Celia R S Garcia; Ju Chen; Michael H Nathanson
Journal:  Hepatology       Date:  2010-07       Impact factor: 17.425

5.  Type I, II, and III inositol 1,4,5-trisphosphate receptors are unequally susceptible to down-regulation and are expressed in markedly different proportions in different cell types.

Authors:  R J Wojcikiewicz
Journal:  J Biol Chem       Date:  1995-05-12       Impact factor: 5.157

6.  Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity.

Authors:  Lale Ozcan; Catherine C L Wong; Gang Li; Tao Xu; Utpal Pajvani; Sung Kyu Robin Park; Anetta Wronska; Bi-Xing Chen; Andrew R Marks; Akiyoshi Fukamizu; Johannes Backs; Harold A Singer; John R Yates; Domenico Accili; Ira Tabas
Journal:  Cell Metab       Date:  2012-04-12       Impact factor: 27.287

7.  Modulation of inositol 1,4,5-trisphosphate receptor type 2 channel activity by Ca2+/calmodulin-dependent protein kinase II (CaMKII)-mediated phosphorylation.

Authors:  Joshua T Maxwell; Sankar Natesan; Gregory A Mignery
Journal:  J Biol Chem       Date:  2012-09-26       Impact factor: 5.157

8.  Lipid rafts establish calcium waves in hepatocytes.

Authors:  Jun Nagata; Mateus T Guerra; Christine A Shugrue; Dawidson A Gomes; Naoki Nagata; Michael H Nathanson
Journal:  Gastroenterology       Date:  2007-04-11       Impact factor: 22.682

9.  Inositol-1,4,5-trisphosphate receptor regulates hepatic gluconeogenesis in fasting and diabetes.

Authors:  Yiguo Wang; Gang Li; Jason Goode; Jose C Paz; Kunfu Ouyang; Robert Screaton; Wolfgang H Fischer; Ju Chen; Ira Tabas; Marc Montminy
Journal:  Nature       Date:  2012-04-08       Impact factor: 49.962

10.  Selective coupling of type 6 adenylyl cyclase with type 2 IP3 receptors mediates direct sensitization of IP3 receptors by cAMP.

Authors:  Stephen C Tovey; Skarlatos G Dedos; Emily J A Taylor; Jarrod E Church; Colin W Taylor
Journal:  J Cell Biol       Date:  2008-10-20       Impact factor: 10.539

View more
  3 in total

1.  Type 3 Inositol 1,4,5-Trisphosphate Receptor Is Increased and Enhances Malignant Properties in Cholangiocarcinoma.

Authors:  Pimwipa Ueasilamongkol; Tanaporn Khamphaya; Mateus T Guerra; Michele A Rodrigues; Dawidson A Gomes; Yong Kong; Wei Wei; Dhanpat Jain; David C Trampert; Meenakshisundaram Ananthanarayanan; Jesus M Banales; Lewis R Roberts; Farshad Farshidfar; Michael H Nathanson; Jittima Weerachayaphorn
Journal:  Hepatology       Date:  2019-08-19       Impact factor: 17.425

2.  Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5-trisphosphate receptor.

Authors:  Tanaporn Khamphaya; Natsasi Chukijrungroat; Vitoon Saengsirisuwan; Kisha A Mitchell-Richards; Marie E Robert; Albert Mennone; Meenakshisundaram Ananthanarayanan; Michael H Nathanson; Jittima Weerachayaphorn
Journal:  Hepatology       Date:  2018-01-02       Impact factor: 17.425

Review 3.  Inositol 1,4,5-trisphosphate receptor in the liver: Expression and function.

Authors:  Fernanda de Oliveira Lemos; Rodrigo M Florentino; Antônio Carlos Melo Lima Filho; Marcone Loiola Dos Santos; M Fatima Leite
Journal:  World J Gastroenterol       Date:  2019-11-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.